Wearable Activity Tracking Device Use in an Adolescent Weight Management Clinic: A Randomized Controlled Pilot Trial
Table 1
Baseline characteristics.
Overall (n = 48)
ATI (n = 18)
Control (n = 30)
value
Age, years, mean, SD
14.48 (1.7)
14.5 (1.58)
14.47 (1.8)
0.94
Sex, n (%)
1.00
Male
24 (50)
9 (50)
15 (50)
Female
24 (50)
9 (50)
15 (50)
Race/ethnicity, n (%)
1.00
NH white
14 (29.17)
5 (27.78)
9 (30)
Hispanic
27 (56.25)
10 (55.56)
17 (56.67)
NH black
7 (14.58)
3 (16.67)
4 (13.33)
BMI, kg/m2 mean, SD
37.49 (8.95)
36.12 (5.9)
38.3 (10.38)
0.36
Hypertension, n (%)
1.00
Yes
2 (4.17)
1 (5.56)
1 (3.33)
No
46 (95.83)
17 (94.44)
29 (96.67)
OSA, n (%)
1.00
Yes
5 (10.42)
2 (11.76)
3 (10)
No
42 (87.5)
15 (88.24)
27 (90)
Asthma, n (%)
0.45
Yes
9 (18.75)
2 (11.11)
7 (23.33)
No
39 (81.25)
16 (88.89)
23 (76.67)
GERD, n (%)
1.00
Yes
1 (2.08)
0 (0)
1 (3.33)
No
47 (97.92)
18 (100)
29 (96.67)
Diabetes mellitus, n (%)
0.62
Yes
4 (8.33)
2 (11.11)
2 (6.67)
No
44 (91.67)
16 (88.89)
28 (93.33)
Drug use, n (%)
0.52
Yes
2 (4.17)
0 (0)
2 (6.67)
No
46 (95.83)
18 (100)
28 (93.33)
Alcohol use, n (%)
0.35
Yes
5 (10.42)
3 (16.67)
2 (6.67)
No
43 (89.58)
15 (83.33)
28 (93.33)
ATI, activity tracking intervention; NH, non-Hispanic; BMI, body mass index; OSA, obstructive sleep apnea; GERD, gastroesophageal reflux disease continuous variables are tested with independent t-test. Categorical variables are tested with chi-square test. Fisher’s exact test () was used when 25% of cells had less than 5 expected counts.
